Latest

09:46
[ ETF Financing Ranking | Guotai CSI All Share Investment Banking & Brokerage ETF (512880) had a net financing buy-in of CNY 68.77 million on Sep 2 ] Sep 2, 2026, Guotai CSI All Share Investment Banking & Brokerage ETF (512880.SH) had a net financing buy-in of CNY 68.77 million.
Tag： Guotai CSI All Share Investment Banking & Brokerage ETF512880.SH
09:46
[ ETF Financing Ranking | GF CSI Innovative Drugs Industry ETF (515120) had a net financing buy-in of CNY 33.38 million on Sep 2 ] Sep 2, 2026, GF CSI Innovative Drugs Industry ETF (515120.SH) had a net financing buy-in of CNY 33.38 million.
Tag： GF CSI Innovative Drugs Industry ETF515120.SHNewTimeSpace
09:46
[ ETF Financing Ranking | Bosera S&P 500 ETF (513500) had a net financing buy-in of CNY 26.52 million on Sep 2 ] Sep 2, 2026, Bosera S&P 500 ETF (513500.SH) had a net financing buy-in of CNY 26.52 million.
Tag： Bosera S&P 500 ETF513500.SHNewTimeSpace
09:46
[ ETF Financing Ranking | Huatai-PB CSI Dividend Low Volatility ETF (512890) had a net financing buy-in of CNY 104.43 million on Sep 2 ] Sep 2, 2026, Huatai-PB CSI Dividend Low Volatility ETF (512890.SH) had a net financing buy-in of CNY 104.43 million.
Tag： Huatai-PB CSI Dividend Low Volatility ETF512890.SHNewTimeSpace
09:24
[ CENTURY GP INTL (02113.HK) plans to issue in total 160.95 million shares by subscription, with estimated net proceeds of HKD 43.3 million ] CENTURY GP INTL (02113.HK) plans to issue in total 160.95 million shares by subscription, with estimated net proceeds of HKD 43.3 million.
Tag： CENTURY GP INTL02113.HKNewTimeSpace
08:03
[ IMPACT THERAP-B (07630.HK): Executive director and CEO increases stake with purchase of 100,000 shares, holding rises to approximately 6.564% ] On 3 September 2026, IMPACT THERAP-B (07630.HK) announced that executive director and CEO Dr. Cai Suixiong purchased 100,000 shares on the open market at an average price of approximately HKD 14.6105 per share (approximately 0.035% of the issued shares), raising his holding to 18,540,884 shares, approximately 6.564%; Dr. Cai did not rule out further increases.
Tag： IMPACT THERAP-B07630.HKShare Increase
07:59
[ ANJI MICRO (688019.SH): Files H-share issuance and listing application with HKEX ] On 3 September 2026, ANJI MICRO (688019.SH) announced that it had filed its H-share issuance and listing application with HKEX in confidential form on 2 September 2026, and will complete the CSRC filing procedures as required; the issuance and listing remains subject to approvals from the CSRC, the Hong Kong Securities and Futures Commission and HKEX, and there remains uncertainty.
Tag： ANJI MICRO688019.SHIPOA+Hfile a listing application
07:57
[ CH BIOTECH SER (08037.HK): Penbo (Hainan) BNCT hospital enters into cross-border oncology cooperation agreement with Hong Kong Oncare ] On 2 September 2026, CH BIOTECH SER (08037.HK) announced that its Penbo (Hainan) BNCT Hospital has entered into a framework cooperation agreement with Oncare Cancer Centre of Hong Kong to establish cross-border oncology cooperation under an "overseas assessment, domestic treatment, overseas follow-up" model; the Hospital operates in the Boao Lecheng pilot zone, and the first 10 head and neck cancer patients achieved an overall response rate of 80%.
Tag： CH BIOTECH SER08037.HKstrategic cooperation
07:53
[ HATCHER GROUP (08365.HK): Updates low-altitude economy investment, project to secure RMB 2 billion financing and 2,000-unit drone purchase commitment ] On 2 September 2026, HATCHER GROUP (08365.HK) provided an update on its low-altitude economy investment: Hong Kong Cross-border signed a strategic investment LOI with Pengcheng Linghang for Greater Bay Area cross-border drone logistics cooperation, under which Pengcheng Linghang committed to purchase 2,000 drones and lead financing of no less than RMB 2 billion; the Company's stake in Hong Kong Cross-border has been reduced from 51% to 15%, and the LOI is not legally binding.
Tag： HATCHER GROUP08365.HKstrategic cooperation
07:44
[ AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit ] On 3 September 2026, AKESO (09926.HK) announced that the OS interim analysis of the HARMONi-2 study of ivonescimab (PD-1/VEGF) as first-line treatment for PD-L1-positive NSCLC met the key secondary OS endpoint with statistical significance and clinical benefit; the study had previously met its primary PFS endpoint (median PFS 11.14 vs 5.82 months, HR=0.51).
Tag： AKESO09926.HKR&D Progress
07:41
[ CHINAGOLDINTL (02099.HK): Selected for inclusion in Hang Seng Momentum Index and Hang Seng HK Stock Connect SOE Quality Index ] On 3 September 2026, CHINAGOLDINTL (02099.HK) announced its inclusion in the Hang Seng Momentum Index and the Hang Seng HK Stock Connect SOE Quality Index, with the change to take effect after the market close on 4 September and from 7 September; the Company stated it will continue to advance key projects including the Jiama Mine expansion and underground mining construction at the Changshanhao Gold Mine.
Tag： CHINAGOLDINTL02099.HKIndex InclusionHang Seng Index
07:39
[ CUTIA-B (02487.HK): BLA for CU-20101 botulinum toxin type A for injection accepted by NMPA ] On 3 September 2026, CUTIA-B (02487.HK) announced that the BLA for CU-20101 (botulinum toxin type A for injection) has been accepted by the NMPA for the indication of improving moderate to severe glabellar lines; the product's manufacturing process will not use animal-derived materials or human serum albumin, aiming to eliminate the risks of TSE infection and allergic reactions.
Tag： CUTIA-B02487.HKR&D ProgressNew Drug Marketing Application
07:34
[ LEADER EDU (01449.HK): Controlling shareholder Shuren agrees to sell 29.9% stake to Scienjoy for approximately HKD 102.69 million ] On 2 September 2026, LEADER EDU (01449.HK) announced that its controlling shareholder Shuren Education entered into a sale and purchase agreement with Scienjoy Innovation Labs Inc. to sell 239,234,000 shares (approximately 29.9%) for approximately HKD 102.69 million; upon completion, Shuren together with Junhua Education will still hold 32.18% and remain the controlling shareholders, and the sale is subject to conditions precedent and may or may not proceed.
Tag： LEADER EDU01449.HKReduction of Holdings
22:08
[ HATCHER GROUP (08365.HK): Shareholder Buys Back 36% Stake in Target Company for HKD 1, Cutting Group's Stake to 15%; Target Signs Strategic Investment LOI for Low-Altitude Economy Project ] On 2 September 2026, Hatcher Group Limited (HATCHER GROUP, 08365.HK) published a further voluntary announcement stating that Qianyi Intelligent Technology Co., Ltd. had bought back 36% of the company's interest in Hong Kong KuaJingTong Aviation Technology Co., Ltd. for HKD 1, reducing the group's stake from 51% to 15% upon completion; Hong Kong KuaJingTong has signed a strategic investment LOI with Shenzhen Pengcheng Linghang Low-altitude Industry Co., Ltd. to pursue a low-altitude economy cross-border logistics project, under which Pengcheng Linghang plans to transfer 10% of its equity, commit to purchasing 2,000 commercial drones and lead the introduction of no less than RMB 2 billion in funding. The LOI is not legally binding and the contemplated transactions may not proceed.
Tag： HATCHER GROUP08365.HKstrategic cooperation
22:06
[ C HEALTH GP (08225.HK): Provides Update on Receivables Recovery; Applies to Set Aside Rejected Arbitration Award against Related Party, Collects RMB 2.088 Million from Cooperative Customers since June ] On 2 September 2026, China Health Group Inc. (C HEALTH GP, 08225.HK) announced, on a voluntary basis, an update on its receivables recovery: receivables with a carrying amount of RMB 128 million as of 31 December 2024 have been fully provided for; after its arbitration claims against a related party were dismissed in full, the company has applied to set aside the arbitration award and is following up on the court's review; newly collected amounts from customers with a positive repayment attitude totaled RMB 2.088 million since 3 June 2026; and the company has established a receivables management committee to strengthen collection and internal controls, with the final recovery outcome subject to uncertainty.
Tag： C HEALTH GP08225.HKReceivables Collection
22:04
[ VGT (02476.HK): Third-Level Wholly-Owned Subsidiaries Sign Maximum Guarantee Agreements, Providing Mutual Guarantees of RMB 30 Million within Annual Guarantee Limit ] On 2 September 2026, Victory Giant Technology (HuiZhou) Co., Ltd. (VGT, 02476.HK) published an overseas regulatory announcement in which its A-share unit (300476) disclosed the progress of guarantees between its third-level wholly-owned subsidiaries: Hunan MFS Technology (PCB) Co., Ltd. and Hunan MFS Technology (Hunan) Co., Ltd. signed maximum guarantee agreements with China CITIC Bank Changsha Branch, providing mutual joint and several liability guarantees of RMB 30 million in aggregate; the amounts fall within the company's 2026 estimated guarantee quota of no more than RMB 2,634.45 million and require no further approval. The aggregate outstanding guarantee balance stood at RMB 2,244.3084 million as of the disclosure date, equivalent to 13.51% of audited net assets at end-2025, with no guarantees to entities outside the consolidation scope and no overdue guarantees.
Tag： VGT02476.HKGuarantee
21:40
[ KEYMED BIO-B (02162.HK): Exclusive License Agreement for Stapokibart Covering 18 Countries and Regions Including Southeast Asia and Central Asia ] On 2 September 2026, Keymed Biosciences Inc. (KEYMED BIO-B, 02162.HK) announced an exclusive license agreement with multinational pharmaceutical company Aeira Pte. Ltd. for the registration and commercialization of its in-house developed IL-4Rα monoclonal antibody Stapokibart injection (Kangyueda) in 18 countries and regions — 11 in Southeast Asia, 5 in Central Asia, plus Hong Kong and Macao; Keymed will receive an upfront payment, milestone payments and high-double-digit royalties based on net sales, and will continue to handle manufacturing and supply.
Tag： KEYMED BIO-B02162.HKLicensing
21:36
[ VIVA GOODS (00933.HK): Acquires Further 17,253,500 Li Ning Shares on Open Market for about HKD 228,207,000; Stake to Rise to about 17.58% ] On 2 September 2026, Viva Goods Company Limited (VIVA GOODS, 00933.HK) announced that its wholly-owned subsidiary had acquired a further 17,253,500 shares of Li Ning Company Limited (LI NING, 02331.HK) on the open market through the Stock Exchange, representing approximately 0.67% of Li Ning's issued share capital, for a total consideration of approximately HKD 228,207,000 at an average price of approximately HKD 13.23 per share; upon completion, Viva Goods' stake in Li Ning rose from approximately 16.91% to 17.58%, with Li Ning continuing to be accounted for as an associate.
Tag： VIVA GOODS00933.HKacquisition
21:34
[ OCUMENSION-B (01477.HK): Phase III Trial of Dry Eye Drug OT-211 Completes Enrollment of 398 Patients in China ] On 2 September 2026, Ocumension Therapeutics (OCUMENSION-B, 01477.HK) announced that its Phase III clinical trial of OT-211 (TRYPTYR, acoltremon ophthalmic solution 0.003%) in China has completed enrollment of an aggregate of 398 patients; the drug is the first TRPM8 agonist approved by the US FDA for the treatment of dry eye disease, and the company secured an exclusive license for the Chinese mainland through a strategic collaboration with Alcon in October 2024.
Tag： OCUMENSION-B01477.HKR&D Progress
21:32
[ GLOBAL BIO-CHEM (00809.HK): Boiler Renovation Project Completed and Commissioned; Coenzyme Q10 Project Civil Works Started at Dehui Base ] On 2 September 2026, Global Bio-chem Technology Group Company Limited (GLOBAL BIO-CHEM, 00809.HK) announced that the completion and ignition ceremony of its boiler renovation project was held at its Dehui production base in Jilin Province on 31 August 2026, with the renovated boilers formally put into operation; civil works for the coenzyme Q10 project commenced on the same day, under which its indirect wholly-owned subsidiary Dacheng Dahe produces CoQ10 mycelium for Shenzhou Bio-tech Co., Ltd., marking the Group's entry into synthetic biology and its expansion into medical applications.
Tag： GLOBAL BIO-CHEM00809.HKProduction Launch
Previous1..8687 888990..576     576 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments